RA Capital Management bought 9,078,529 derivative securities in Tyra Biosciences at $22.03 per share on Sep. 15, taking its holding to 11,616,986. The purchase represented about 78.1% of RA Capital Management’s resulting derivative securities position, giving investors a stated measure of the transaction’s size within its post-purchase holding.
Key Highlights
- RA Capital Management’s post-transaction position in Tyra Biosciences stood at 11,616,986 derivative securities.
- The purchase price was $22.03 per share on Sep. 15, 2026.
- Transaction code P identifies the activity as an open-market purchase.
Tyra Biosciences, Inc. (NASDAQ: TYRA) is a biotechnology company. RA Capital Management, L.P. purchased 9,078,529 derivative securities in Tyra Biosciences at $22.03 per share on Sep. 15, lifting its resulting position to 11,616,986 derivative securities.
RA Capital Management Buys 9,078,529 Securities
The acquired securities were derivative securities of Tyra Biosciences, and the stated price was $22.03 per share.
Purchase Represents 78.1% of Resulting Holding
RA Capital Management’s resulting derivative securities position was 11,616,986. The transaction represented about 78.1% of that post-purchase holding. The transaction date was Sep. 15, 2026. The reported details pair the purchase with a per-share price of $22.03 and identify RA Capital Management, L.P. as the insider involved.
FAQs
Q: How many Tyra Biosciences derivative securities did RA Capital Management buy?
A: RA Capital Management bought 9,078,529 derivative securities in Tyra Biosciences. The transaction was recorded as an insider purchase at $22.03 per share.
Q: What percentage of RA Capital Management’s Tyra Biosciences holding did the purchase represent?
A: The purchase represented about 78.1% of RA Capital Management’s resulting derivative securities holding in Tyra Biosciences. The resulting position was 11,616,986 securities.
Q: When did RA Capital Management buy Tyra Biosciences securities?
A: RA Capital Management completed the reported Tyra Biosciences purchase on Sep. 15, 2026. The transaction price was $22.03 per share, and the code was P.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.